所有图片(1)
About This Item
经验公式（希尔记法）:
C26H33NO2
CAS号:
分子量:
391.55
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 5 mg/mL, clear
储存温度
−20°C
SMILES字符串
C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5
InChI
1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
InChI key
UVIQSJCZCSLXRZ-UBUQANBQSA-N
基因信息
human ... CYP17A1(1586)
正在寻找类似产品? 访问 产品对比指南
应用
醋酸阿比特龙已被用于研究其抗肿瘤操作的三维微小肿瘤平台。
生化/生理作用
醋酸阿比特龙是阿比特龙的前药，是 CYP17A1 (CYP450c17) 的强效、选择性和口服生物利用度抑制剂，CYP17A1 是催化两个关键系列反应（17α羟化酶和 17，20 裂解酶）在雄激素和雌激素生物合成中导致 DHEA 和雄烯二酮的形成，最终可能被代谢为睾酮。CYP17 是睾丸和肾上腺中雄激素生物合成的关键酶，因此对它的抑制应停止两地雄激素的产生。醋酸阿比特龙用于治疗转移性去势抵抗性前列腺癌。 醋酸阿比特龙在多西他赛治疗后 CRPC（去势抵抗性前列腺癌）患者中具有显著的抗肿瘤活性。对睾丸、肾上腺和前列腺组织中的雄激素生物合成高度必需。
警示用语：
Danger
危险声明
危险分类
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
靶器官
Endocrine system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
其他客户在看
Gerhardt Attard et al.
Cancer research, 69(12), 4937-4940 (2009-06-11)
Abiraterone acetate is a potent, selective, and orally bioavailable small molecule inhibitor of CYP17, an enzyme that catalyzes two key serial reactions (17 alpha hydroxylase and 17,20 lyase) in androgen and estrogen biosynthesis. Clinical trials have confirmed that specific inhibition
Charles J Ryan et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(9), 1481-1488 (2010-02-18)
Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant prostate cancers (CRPCs), extragonadal androgen sources may sustain tumor growth despite a castrate environment. This phase
Daniel C Danila et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(9), 1496-1501 (2010-02-18)
Persistence of ligand-mediated androgen receptor signaling has been documented in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and selective inhibitor of CYP17, which is required for androgen biosynthesis in the testes, adrenal glands, and prostate tissue. This
Alison H M Reid et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(9), 1489-1495 (2010-02-18)
The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC). In this multicenter, two-stage, phase II study, abiraterone acetate 1,000
E David Crawford et al.
The Journal of urology, 194(6), 1537-1547 (2015-07-22)
The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal sequencing strategies and resistance patterns. A comprehensive review of efficacy and safety data for new agents and current knowledge
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门